---
title: "MiNK Therapeutics (INKT) stock: news and investor profile"
url: "https://aibio.space/companies/mink-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "MiNK Therapeutics, Inc. (NASDAQ: INKT), United States. The directory classifies it as Biotechnology."
---

INKT MiNK Therapeutics, Inc. NASDAQ · United States

# MiNK Therapeutics (INKT) news

Company Updates · 2026-08-13

## [MiNK reports second quarter 2026 results and early trial observations](https://aibio.space/news/mink-reports-second-quarter-2026-results-early-trial-observations/)

MiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury.

## Latest MiNK Therapeutics news

1. 2026-05-15 Company Updates [MiNK starts randomized Phase 2 trial in acute lung injury](https://aibio.space/news/mink-starts-randomized-phase-2-trial-acute-lung-injury/) MiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026.
2. 2025-10-09 Financings [Agenus takes up to $10,000,000 loan from Zydus, pledges 822,910 MiNK shares](https://aibio.space/news/agenus-takes-up-10-000-000-loan-zydus-pledges-822-910-mink-shares/) The note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.

## MiNK Therapeutics at a glance

- **Ticker**: INKT

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $8.8 million

### Related companies

- [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA
- [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG
- [SpyGlass Pharma](https://aibio.space/companies/spyglass-pharma/) NASDAQ: SGP
- [Alaunos Therapeutics](https://aibio.space/companies/alaunos-therapeutics/) NASDAQ: TCRT
- [Xencor](https://aibio.space/companies/xencor/) NASDAQ: XNCR
- [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) NASDAQ: VYGR
- [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD
- [MeiraGTx Holdings](https://aibio.space/companies/meiragtx/) NASDAQ: MGTX

### Also on NASDAQ

- [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) PBYI
- [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) VIR
- [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) DYN
- [Immatics](https://aibio.space/companies/immatics-n-v/) IMTX
- [LAKELAND INDUSTRIES INC](https://aibio.space/companies/lakeland-industries/) LAKE
- [Profound Medical](https://aibio.space/companies/profound-medical/) PROF

## MiNK Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) |
| Net income (loss) | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) |
| Cash from operations | [-$5.9 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) | [-$9.6 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) |
| Cash and equivalents | [$13.4 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526349309/) | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about MiNK Therapeutics

What is the ticker symbol of MiNK Therapeutics?

MiNK Therapeutics, Inc. trades under the ticker INKT on NASDAQ.

Where is MiNK Therapeutics listed?

MiNK Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6Q40.

What is the SEC CIK of MiNK Therapeutics?

The SEC Central Index Key (CIK) for MiNK Therapeutics, Inc. is 1840229. Its filings are on SEC EDGAR.

How many shares does MiNK Therapeutics have outstanding?

5,103,002 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is MiNK Therapeutics listed under?

Our directory records MiNK Therapeutics, Inc. under United States.

What does MiNK Therapeutics do?

Our directory classifies MiNK Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of MiNK Therapeutics?

The ISIN recorded for MiNK Therapeutics, Inc. is US6036932019.

Does aibio.space cover MiNK Therapeutics?

aibio.space lists MiNK Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is MiNK Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is MiNK Therapeutics profitable?

MiNK Therapeutics, Inc. reported a net loss of $12.5 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.

How much does MiNK Therapeutics spend on research and development?

$5.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does MiNK Therapeutics have?

$8.8 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest MiNK Therapeutics (INKT) stock news?

Our latest story on MiNK Therapeutics, dated Aug 13, 2026: "MiNK reports second quarter 2026 results and early trial observations". MiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury. [Source](https://aibio.space/news/mink-reports-second-quarter-2026-results-early-trial-observations/).

What is MiNK Therapeutics's market cap?

We do not publish live share prices. In its annual report, MiNK Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $10.9 million as of Jun 30, 2025.

Is MiNK Therapeutics a smaller reporting company?

SEC records list MiNK Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.

## Investor discussion: MiNK Therapeutics

Members talk about MiNK Therapeutics (INKT). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at MiNK Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/inkt-20251231.htm)
2. 2025-11-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000119312525272532/d62147ds3.htm)
3. 2025-08-22 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000119312525186417/d891898d424b5.htm)
4. 2025-07-15 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000119312525159014/d96690d424b5.htm)
5. 2025-03-18 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000095017025041379/inkt-20241231.htm)
6. 2025-01-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840229/000119312525009595/d926991d8k.htm)
7. 2024-12-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000114036124050096/ny20039626x2_def14a.htm)
8. 2024-12-06 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1840229/000114036124048693/ny20039626x1_pre14a.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INKT on TradingView](https://www.tradingview.com/symbols/NASDAQ-INKT/).

## SEC filings and registration

- **SEC name**: MiNK Therapeutics, Inc.

- **CIK**: 1840229

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: INKT (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 149 FIFTH AVENUE, NEW YORK, NY, 10010

- **Phone**: 212-994-8250

- **Shares outstanding**: 5,103,002 as of 2026-08-11 (10-Q filed 2026-08-13)

- **Former names**: AgenTus Therapeutics, Inc.; AgenTus Therapeutics, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1840229/000119312526349309/inkt-20260630.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-20260813.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1840229/000119312526278642/inkt-20260617.htm) filed 2026-06-23
- [10-Q](https://www.sec.gov/Archives/edgar/data/1840229/000119312526226804/inkt-20260331.htm) filed 2026-05-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/inkt-20260515.htm) filed 2026-05-15
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1840229/000119312526197577/mink-def_14a_2026.htm) filed 2026-04-30
- [10-K](https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/inkt-20251231.htm) filed 2026-03-31
- [8-K](https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/inkt-20260331.htm) filed 2026-03-31

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001840229), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

MiNK Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INKT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: MiNK Therapeutics, Inc.

- **Ticker**: INKT

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US6036932019

- **Other listed symbols**: GETTEX:6Q40

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INKT/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/mink-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MiNK Therapeutics (INKT) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/mink-therapeutics/